A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Autor: Simonsson, Bengt *, Gedde-Dahl, Tobias *, Markevärn, Berit *, Remes, Kari *, Stentoft, Jesper *, Almqvist, Anders *, Björeman, Mats *, Flogegård, Max *, Hallman, Heikki *, Koskenvesa, Perttu *, Lindblom, Anders *, Malm, Claes *, Mustjoki, Satu, Myhr-Eriksson, Kristina *, Räsänen, Anu *, Sinisalo, Marjatta *, Sippola, Risto *, Själander, Anders *, Strömberg, Ulla *, Bjerrum, Ole Weiss *, Ehrencrona, Hans *, Gruber, Franz *, Kairisto, Veli *, Olsson, Karin RN *, Nagler, Arnon *, Nielsen, Johan Lanng *, Hjorth-Hansen, Henrik *, Porkka, Kimmo, for the Nordic CML Study Group (NCMLSG)
Zdroj: In Blood 20 November 2009 114(22):3280-3280
Databáze: ScienceDirect